Outpace Bio vs Neuralink
Side-by-side comparison of AI visibility scores, market position, and capabilities
Outpace Bio is a clinical-stage biotech using AI-powered protein design and synthetic biology to develop next-generation cell therapies targeting solid tumors; founded by pioneers in CAR-T and protein engineering; raised $109M Series B in 2024;
About
Outpace Bio is a clinical-stage biotechnology company headquartered in Seattle, Washington, founded to address one of the most significant unmet needs in oncology: creating effective cell therapies for solid tumors. While CAR-T cell therapies have transformed treatment of blood cancers, they have largely failed against solid tumors due to the immunosuppressive tumor microenvironment, T-cell exhaustion, and tumor heterogeneity. Outpace Bio applies AI-powered protein design and synthetic biology to engineer novel cellular logic circuits — custom genetic programs embedded in therapeutic T cells — that allow the cells to sense the tumor environment and respond adaptively rather than becoming exhausted or suppressed.
Pioneer of implantable BCIs with 12+ active human patients as of Sep 2025; raised $650M Series E in Apr 2026 led by ARK Invest and Sequoia at a ~$14.9B valuation; mass production underway.
About
Neuralink is a neurotechnology company founded in 2016 by Elon Musk and a team of neuroscientists and engineers, developing implantable brain-computer interface devices that enable individuals with paralysis to control digital devices directly with their thoughts. The company's first commercial product, the N1 implant, is a coin-sized device containing 1,024 electrodes that is surgically placed in the motor cortex. As of September 2025, twelve patients worldwide had received the N1 implant and were actively using it to control computers, smartphones, and robotic arms with neural signals alone.
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.